Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery
Authors:
- 12 December 2024
- journal article
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 45 (4) , 381-386
Abstract
Background: Semaglutide is a medication for weight loss in obese patients. Recently, many plastic surgeons have recommended semaglutide following bariatric surgery to increase weight loss. However, postoperative complications such as wound dehiscence, delayed healing, and infection pose significant risks. Objectives: In this study we aimed to examine the relationship between preoperative semaglutide and postoperative complications in nondiabetic obese patients undergoing body contouring surgery. We hypothesized that semaglutide would increase the risk of postoperative complications. Methods: In this retrospective cohort study we utilized the TriNetX Research database. Nondiabetic patients who underwent body contouring surgery between 2021 and 2024 after bariatric procedures were included. Patients were divided into 2 cohorts: Cohort A (4215 patients), which received semaglutide for ≥6 months before surgery, and Cohort B (104,927 patients), without semaglutide. Propensity score matching was employed to create comparable cohorts based on age, gender, race, and BMI. The primary outcomes included postoperative complications within 30 days of surgery. Results: Significant differences were found between the cohorts. Semaglutide patients had higher rates of wound dehiscence (5.19% vs 2.78%, P < .0001); delayed wound healing (2.58% vs 1.21%, P < .0001); surgical site infections (5.37% vs 2.87%, P < .0001); nausea, vomiting, and diarrhea (11.27% vs 5.34%, P < .0001); hypertrophic scar formation (5.53% vs 3.86%, P = .0011); and surgical site pain (6.05% vs 3.29%, P < .0001). Conclusions: Preoperative semaglutide in nondiabetic patients undergoing body contouring surgery following bariatric procedures is associated with higher rates of adverse postoperative outcomes. These findings highlight the need for enhanced preoperative counseling and surgical planning to minimize risks and improve patient outcomes. Level of Evidence: 3 (Therapeutic):Keywords
Funding Information
- UTMB Institute for Translational Sciences (UL1 TR001439)
- National Center for Advancing Translational Sciences
- National Institutes of Health
- NIH
This publication has 30 references indexed in Scilit:
- Anti-inflammatory benefits of semaglutide: State of the artJournal of Clinical & Translational Endocrinology, 2024
- The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical OpportunitiesCurrent Obesity Reports, 2023
- Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or ObesityJAMA Network Open, 2022
- A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesityComputers in Biology and Medicine, 2021
- Exercise and metabolic health: beyond skeletal muscleDiabetologia, 2020
- Preoperative Medical Weight Management in Bariatric Surgery: a Review and ReconsiderationObesity Surgery, 2016
- Enhanced Recovery After Body-Contouring Surgery: Reducing Surgical Complication Rates by Optimizing NutritionAesthetic Plastic Surgery, 2010
- Body Contouring Surgery Following Bariatric Surgery and Dietetically Induced Massive Weight Reduction: A Risk AnalysisObesity Surgery, 2008
- Relationship of body mass index with demographic and clinical characteristics in the Longitudinal Assessment of Bariatric Surgery (LABS)Surgery for Obesity and Related Diseases, 2008
- Preoperative Serum Albumin Level as a Predictor of Operative Mortality and MorbidityArchives of Surgery, 1999